Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Front Oncol ; 12: 941657, 2022.
Article in English | MEDLINE | ID: mdl-36059614

ABSTRACT

Treatment-resistant glioma stem cells are thought to propagate and drive growth of malignant gliomas, but their markers and our ability to target them specifically are not well understood. We demonstrate that podoplanin (PDPN) expression is an independent prognostic marker in gliomas across multiple independent patient cohorts comprising both high- and low-grade gliomas. Knockdown of PDPN radiosensitized glioma cell lines and glioma-stem-like cells (GSCs). Clonogenic assays and xenograft experiments revealed that PDPN expression was associated with radiotherapy resistance and tumor aggressiveness. We further demonstrate that knockdown of PDPN in GSCs in vivo is sufficient to improve overall survival in an intracranial xenograft mouse model. PDPN therefore identifies a subset of aggressive, treatment-resistant glioma cells responsible for radiation resistance and may serve as a novel therapeutic target.

2.
Front Immunol ; 10: 1633, 2019.
Article in English | MEDLINE | ID: mdl-31379836

ABSTRACT

Purine nucleotides and nucleosides are at the center of biologic reactions. In particular, adenosine triphosphate (ATP) is the fundamental energy currency of cellular activity and adenosine has been demonstrated to play essential roles in human physiology and pathophysiology. In this review, we examine the role of purinergic signaling in acute and chronic pulmonary inflammation, with emphasis on ATP and adenosine. ATP is released into extracellular space in response to cellular injury and necrosis. It is then metabolized to adenosine monophosphate (AMP) via ectonucleoside triphosphate diphosphohydrolase-1 (CD39) and further hydrolyzed to adenosine via ecto-5'-nucleotidase (CD73). Adenosine signals via one of four adenosine receptors to exert pro- or anti-inflammatory effects. Adenosine signaling is terminated by intracellular transport by concentrative or equilibrative nucleoside transporters (CNTs and ENTs), deamination to inosine by adenosine deaminase (ADA), or phosphorylation back into AMP via adenosine kinase (AK). Pulmonary inflammatory and hypoxic conditions lead to increased extracellular ATP, adenosine diphosphate (ADP) and adenosine levels, which translates to increased adenosine signaling. Adenosine signaling is central to the pulmonary injury response, leading to various effects on inflammation, repair and remodeling processes that are either tissue-protective or tissue destructive. In the acute setting, particularly through activation of adenosine 2A and 2B receptors, adenosine signaling serves an anti-inflammatory, tissue-protective role. However, excessive adenosine signaling in the chronic setting promotes pro-inflammatory, tissue destructive effects in chronic pulmonary inflammation.


Subject(s)
Pneumonia/metabolism , Purinergic Agents/metabolism , Signal Transduction/physiology , Adenosine Deaminase/metabolism , Adenosine Monophosphate/metabolism , Adenosine Triphosphate/metabolism , Animals , Humans
4.
Cell Rep ; 16(1): 106-119, 2016 06 28.
Article in English | MEDLINE | ID: mdl-27320922

ABSTRACT

The molecular mechanisms of chronic pain are poorly understood and effective mechanism-based treatments are lacking. Here, we report that mice lacking adenosine deaminase (ADA), an enzyme necessary for the breakdown of adenosine, displayed unexpected chronic mechanical and thermal hypersensitivity due to sustained elevated circulating adenosine. Extending from Ada(-/-) mice, we further discovered that prolonged elevated adenosine contributed to chronic pain behaviors in two additional independent animal models: sickle cell disease mice, a model of severe pain with limited treatment, and complete Freund's adjuvant paw-injected mice, a well-accepted inflammatory model of chronic pain. Mechanistically, we revealed that activation of adenosine A2B receptors on myeloid cells caused nociceptor hyperexcitability and promoted chronic pain via soluble IL-6 receptor trans-signaling, and our findings determined that prolonged accumulated circulating adenosine contributes to chronic pain by promoting immune-neuronal interaction and revealed multiple therapeutic targets.


Subject(s)
Adenosine/metabolism , Chronic Pain/metabolism , Nervous System/immunology , Nervous System/pathology , Receptor, Adenosine A2B/metabolism , Adenosine/blood , Adenosine Deaminase/metabolism , Anemia, Sickle Cell/complications , Anemia, Sickle Cell/pathology , Animals , Behavior, Animal , Chronic Pain/blood , Chronic Pain/pathology , Chronic Pain/physiopathology , Disease Models, Animal , Ganglia, Spinal/metabolism , Ganglia, Spinal/pathology , Gene Expression Regulation , Inflammation/pathology , Interleukin-6/metabolism , Mice, Knockout , Myeloid Cells/metabolism , Nervous System/physiopathology , Nociceptors/metabolism , Receptors, Interleukin-6/metabolism , Reflex , STAT3 Transcription Factor/metabolism , Sensory Receptor Cells/pathology , Signal Transduction , Solubility , TRPV Cation Channels/genetics , TRPV Cation Channels/metabolism , Up-Regulation
5.
FASEB J ; 29(1): 50-60, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25318478

ABSTRACT

Idiopathic pulmonary fibrosis (IPF) is a lethal, fibroproliferative disease. Pulmonary hypertension (PH) can develop secondary to IPF and increase mortality. Alternatively, activated macrophages (AAMs) contribute to the pathogenesis of both IPF and PH. Here we hypothesized that adenosine signaling through the ADORA2B on AAMs impacts the progression of these disorders and that conditional deletion of ADORA2B on myeloid cells would have a beneficial effect in a model of these diseases. Conditional knockout mice lacking ADORA2B on myeloid cells (Adora2B(f/f)-LysM(Cre)) were exposed to the fibrotic agent bleomycin (BLM; 0.035 U/g body weight, i.p.). At 14, 17, 21, 25, or 33 d after exposure, SpO2, bronchoalveolar lavage fluid (BALF), and histologic analyses were performed. On day 33, lung function and cardiovascular analyses were determined. Markers for AAM and mediators of fibrosis and PH were assessed. Adora2B(f/f)-LysM(Cre) mice presented with attenuated fibrosis, improved lung function, and no evidence of PH compared with control mice exposed to BLM. These findings were accompanied by reduced expression of CD206 and arginase-1, markers for AAMs. A 10-fold reduction in IL-6 and a 5-fold decrease in hyaluronan, both linked to lung fibrosis and PH, were also observed. These data suggest that activation of the ADORA2B on macrophages plays an active role in the pathogenesis of lung fibrosis and PH.


Subject(s)
Hypertension, Pulmonary/etiology , Idiopathic Pulmonary Fibrosis/etiology , Receptor, Adenosine A2B/deficiency , Animals , Bleomycin/toxicity , Disease Models, Animal , Humans , Hypertension, Pulmonary/pathology , Hypertension, Pulmonary/physiopathology , Idiopathic Pulmonary Fibrosis/pathology , Idiopathic Pulmonary Fibrosis/physiopathology , Macrophage Activation , Mice , Mice, Inbred C57BL , Mice, Knockout , Myeloid Cells/physiology , Receptor, Adenosine A2B/genetics , Receptor, Adenosine A2B/physiology
6.
J Immunol ; 193(7): 3755-68, 2014 Oct 01.
Article in English | MEDLINE | ID: mdl-25172494

ABSTRACT

Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease with progressive fibrosis and death within 2-3 y of diagnosis. IPF incidence and prevalence rates are increasing annually with few effective treatments available. Inhibition of IL-6 results in the attenuation of pulmonary fibrosis in mice. It is unclear whether this is due to blockade of classical signaling, mediated by membrane-bound IL-6Rα, or trans signaling, mediated by soluble IL-6Rα (sIL-6Rα). Our study assessed the role of sIL-6Rα in IPF. We demonstrated elevations of sIL-6Rα in IPF patients and in mice during the onset and progression of fibrosis. We demonstrated that protease-mediated cleavage from lung macrophages was important in production of sIL-6Rα. In vivo neutralization of sIL-6Rα attenuated pulmonary fibrosis in mice as seen by reductions in myofibroblasts, fibronectin, and collagen in the lung. In vitro activation of IL-6 trans signaling enhanced fibroblast proliferation and extracellular matrix protein production, effects relevant in the progression of pulmonary fibrosis. Taken together, these findings demonstrate that the production of sIL-6Rα from macrophages in the diseased lung contributes to IL-6 trans signaling that in turn influences events crucial in pulmonary fibrosis.


Subject(s)
Idiopathic Pulmonary Fibrosis/immunology , Interleukin-6/immunology , Macrophages, Alveolar/immunology , Pulmonary Fibrosis/immunology , Receptors, Interleukin-6/immunology , Signal Transduction/immunology , Animals , Collagen/immunology , Disease Models, Animal , Female , Fibronectins/immunology , Humans , Idiopathic Pulmonary Fibrosis/genetics , Idiopathic Pulmonary Fibrosis/mortality , Idiopathic Pulmonary Fibrosis/pathology , Idiopathic Pulmonary Fibrosis/therapy , Interleukin-6/genetics , Lung/immunology , Lung/pathology , Macrophages, Alveolar/pathology , Male , Mice , Myofibroblasts/immunology , Myofibroblasts/pathology , Pulmonary Fibrosis/genetics , Pulmonary Fibrosis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...